Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | PYCR1 | P32322 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341265 | 1.00 | MEN1 (0.66) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL4352641 | 1.00 | MEN1 (0.66) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL25159497 | 0.94 | MEN1 (0.62) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL10431857 | 0.94 | MEN1 (0.62) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL13993320 | 0.89 | KDM4E (0.70) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL14274010 | 0.89 | KDM4E (0.70) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL28339091 | 0.89 | KDM4E (0.70) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL3235906 | 0.84 | MEN1 (0.66) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL28168731 | 0.84 | MEN1 (0.54) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 | |
| SCHEMBL4347718 | 0.82 | MEN1 (0.63) | MEN1KMT2AKDM4ESMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| EP-2007707-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118041-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007118041-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1594856-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | MEN1 4443/4885KMT2A 2160/4885KDM4E 3936/4885 |
| US-20090275611-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, OPRL1 | MEN1 4775/4885KMT2A 2988/4885KDM4E 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.